FDA cGMP: Requirements, Significance, and Implementation

Author: Maren Fichtner | August 27, 2026

Definition: What is FDA cGMP?

FDA cGMP (Current Good Manufacturing Practice) refers to the U.S. requirements for processes, equipment, personnel, and documentation in pharmaceutical manufacturing, as regulated in 21 CFR Parts 210 and 211. Unlike specific individual regulations such as Part 11, cGMP covers the entire production system: from raw material testing through manufacturing processes and cleaning validation to final inspection and batch release.

Publisher: U.S. Food and Drug Administration (FDA)

Legal basis: 21 CFR Parts 210 and 211

Who is subject to FDA cGMP?

cGMP applies to all manufacturers of drugs marketed in the U.S.—regardless of whether production takes place in the U.S. or abroad. This applies to both manufacturers of finished drug products and suppliers of active pharmaceutical ingredients (APIs) and raw materials that fall within the scope of the regulations as part of the supply chain.

Overview of Core Requirements

Organization and Personnel: Sufficiently qualified and trained personnel for all GMP-related activities
Facilities and Equipment: Suitable , validated facilities and calibrated equipment
Control of Starting Materials: Testing and release of raw materials prior to use in production
Production and Process Controls: Validated manufacturing processes with defined in-process controls
Batch documentation: complete , traceable records of every manufacturing step
Complaint and recall system: structured handling of complaints and product recalls

Difference from EU GMP

FDA cGMP and EU GMP share the same fundamental objective—consistent, quality-assured drug manufacturing—and are largely identical in content, as both are based on the same international principles (including ICH guidelines). The formal difference lies in the legal basis: cGMP is U.S. law codified in 21 CFR Parts 210/211, while EU GMP is regulated in EudraLex Volume 4 and is directly applicable in the member states. Through mutual recognition agreements such as the EU-U.S. Mutual Recognition Agreement, both regions are increasingly recognizing each other’s GMP inspection results, which reduces the double burden on international manufacturers without harmonizing the regulatory frameworks themselves.

Consequences of Noncompliance

cGMP violations are among the most common causes of FDA warning letters and Form 483s. In the event of serious or repeated deficiencies, the FDA may prohibit the import of affected products into the U.S. (Import Alert), suspend market authorization, or, in extreme cases, initiate criminal proceedings. Since cGMP inspections can occur without prior notice, it is essential to maintain a state of readiness for inspections at all times, rather than only when prompted by specific events.

Frequently Asked Questions About FDA cGMP

Is FDA cGMP required by law?

Yes, as a binding U.S. law under 21 CFR Parts 210 and 211 for all manufacturers that supply the U.S. market.

What does the "c" in cGMP stand for?

"Current" – the commitment to consistently use modern, state-of-the-art methods.

What is the difference from EU GMP?

Substantively very similar, but with different legal bases; mutual recognition agreements reduce the need for duplicate efforts.

Who monitors compliance?

The FDA conducts regular and ad hoc inspections, issuing warning letters or Form 483s in the event of violations.

Successfully Implementing FDA cGMP

Since cGMP inspections can occur without prior notice, the key to success is documentation that is complete at all times. Connected worker platforms such as weasl automatically generate batch records, cleaning records, and deviation documentation during the ongoing production process and make them immediately available to the inspector.

Learn more about weasl and download our product flyer now.

FDA cGMP